PMCC Resources

Here are the staff publications for March 2017. 

Compiled by the Health Sciences Library (RMH, RWH, PMCC and Victorian Mental Health) April 3rd 2017.

  1. Agarwal R, Blombery P, McBean M, Jones K, Fellowes A, Doig K, Forsyth C, Westerman DA. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory. Annals of Hematology 2017;96:725-32.
  2. Bibby H, White V, Thompson K, Anazodo A. What Are the Unmet Needs and Care Experiences of Adolescents and Young Adults with Cancer? A Systematic Review. Journal of Adolescent and Young Adult Oncology 2017;6:6-30.
  3. Blaschke S, O'Callaghan CC, Schofield P. Identifying opportunities for nature engagement in cancer care practice and design: protocol for four-round modified electronic Delphi. BMJ Open 2017;7:e013527.
  4. Blaschke S, O'Callaghan CC, Schofield P. "Artificial But Better Than Nothing". Herd 2017;10:51-60.
  5. Bozin M, Lamb A, Putra LJ. Pheochromocytoma with Negative Metanephrines: A Rarity and the Significance of Dopamine Secreting Tumors. Urology case reports 2017;12:51-3.
  6. Cardoso F, Costa A, Senkus E, Aapro M, Andre F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244-259]. Breast 2017;32:269-70.
  7. Chapman B, Slavin M, Marriott D, Halliday C, Kidd S, Arthur I, Bak N, Heath CH, Kennedy K, Morrissey CO, Sorrell TC, van Hal S, Keighley C, Goeman E, Underwood N, Hajkowicz K, Hofmeyr A, Leung M, Macesic N, Botes J, Blyth C, Cooley L, George CR, Kalukottege P, Kesson A, McMullan B, Baird R, Robson J, Korman TM, Pendle S, Weeks K, Liu E, Cheong E, Chen S, Australian, New Zealand Mycoses Interest G. Changing epidemiology of candidaemia in Australia. Journal of Antimicrobial Chemotherapy 2017;72:1103-8.
  8. Cheah CY, Seymour JF. When to treat patients with relapsed follicular lymphoma. Expert Reviews in Hematology 2017;10:187-91.
  9. Cheng Y, Heasman K, Peck S, Peel E, Gooley RM, Papenfuss AT, Hogg CJ, Belov K. Significant decline in anticancer immune capacity during puberty in the Tasmanian devil. Scientific Reports 2017;7:44716.
  10. Corona SP, Ravelli A, Cretella D, Cappelletti MR, Zanotti L, Dester M, Gobbi A, Petronini PG, Generali D. CDK4/6 inhibitors in HER2-positive breast cancer. Critical Reviews in Oncology/Hematology 2017;112:208-14.
  11. Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. Journal of Clinical Oncology 2017;35:826-33.
  12. Dawson MA. The cancer epigenome: Concepts, challenges, and therapeutic opportunities. Science 2017;355:1147-52.
  13. Dunning MJ, Vowler SL, Lalonde E, Ross-Adams H, Boutros P, Mills IG, Lynch AG, Lamb AD. Mining Human Prostate Cancer Datasets: The "camcAPP" Shiny App. EBioMedicine 2017;17:5-6.
  14. Fietz ER, Keenan CR, Lopez-Campos G, Tu Y, Johnstone CN, Harris T, Stewart AG. Glucocorticoid resistance of migration and gene expression in a daughter MDA-MB-231 breast tumour cell line selected for high metastatic potential. Scientific Reports 2017;7:43774.
  15. Forrester HB, de Kretser DM, Leong T, Hagekyriakou J, Sprung CN. Follistatin attenuates radiation-induced fibrosis in a murine model. PLoS One 2017;12:e0173788.
  16. Fu NY, Rios AC, Pal B, Law CW, Jamieson P, Liu R, Vaillant F, Jackling F, Liu KH, Smyth GK, Lindeman GJ, Ritchie ME, Visvader JE. Identification of quiescent and spatially restricted mammary stem cells that are hormone responsive. Nature Cell Biology 2017;19:164-76.
  17. Hicks RJ. Citius, Altius, Fortius: An Olympian Dream for Theranostics. Journal of Nuclear Medicine 2017;58:194-5.
  18. Hiller JG, Sampurno S, Millen R, Kuruvilla N, Ho KM, Ramsay R, Riedel B. Impact of celecoxib on inflammation during cancer surgery: a randomized clinical trial. Canadian Journal of Anaesthesia 2017;64:497-505.
  19. Hirshoren N, Danne J, Dixon BJ, Magarey M, Kleid S, Webb A, Tiong A, Corry J, Gyorki D. Prognostic markers in metastatic cutaneous squamous cell carcinoma of the head and neck. Head & Neck 2017;39:772-8.
  20. Hofman MS, Iravani A. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging. PET Clinics 2017;12:219-34.
  21. Kam J, Kam J, Mann GB, Phillips C, Wentworth JM, King J, Lindeman GJ. Solitary pituitary metastasis from HER2-positive breast cancer. Asia Pacific Journal of Clinical Oncology 2017;13:e181-e4.
  22. Kao CY, Aranda S, Krishnasamy M, Hamilton B. Interventions to improve patient understanding of cancer clinical trial participation: a systematic review. European Journal of Cancer Care (Engl) 2017;26.
  23. Kentwell M, Dow E, Antill Y, Wrede CD, McNally O, Higgs E, Hamilton A, Ananda S, Lindeman GJ, Scott CL. Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics. Gynecologic Oncology 2017;145:130-6.
  24. Kerry LE, Pegg EE, Cameron DP, Budzak J, Poortinga G, Hannan KM, Hannan RD, Rudenko G. Selective inhibition of RNA polymerase I transcription as a potential approach to treat African trypanosomiasis. PLoS Neglected Tropical Diseases 2017;11:e0005432.
  25. Lefebure M, Tothill RW, Kruse E, Hawkins ED, Shortt J, Matthews GM, Gregory GP, Martin BP, Kelly MJ, Todorovski I, Doyle MA, Lupat R, Li J, Schroeder J, Wall M, Craig S, Poortinga G, Cameron D, Bywater M, Kats L, Gearhart MD, Bardwell VJ, Dickins RA, Hannan RD, Papenfuss AT, Johnstone RW. Genomic characterisation of Emu-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene. Nature Communications 2017;8:14581.
  26. Liu DS, Duong CP, Haupt S, Montgomery KG, House CM, Azar WJ, Pearson HB, Fisher OM, Read M, Guerra GR, Haupt Y, Cullinane C, Wiman KG, Abrahmsen L, Phillips WA, Clemons NJ. Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation. Nature Communications 2017;8:14844.
  27. Mardiana S, John LB, Henderson MA, Slaney CY, von Scheidt B, Giuffrida L, Davenport AJ, Trapani JA, Neeson PJ, Loi S, Haynes NM, Kershaw MH, Beavis PA, Darcy PK. A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells. Cancer Research 2017;77:1296-309.
  28. Mbeutcha A, Roupret M, Kamat AM, Karakiewicz PI, Lawrentschuk N, Novara G, Raman JD, Seitz C, Xylinas E, Shariat SF. Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. World Journal of Urology 2017;35:337-53.
  29. Michael M, Garcia-Carbonero R, Weber MM, Lombard-Bohas C, Toumpanakis C, Hicks RJ. The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review. Oncologist 2017;22:272-85.
  30. Miranda PJ, Buckley D, Raghu D, Pang JB, Takano EA, Vijayakumaran R, Teunisse AF, Posner A, Procter T, Herold MJ, Gamell C, Marine JC, Fox SB, Jochemsen A, Haupt S, Haupt Y. MDM4 is a rational target for treating breast cancers with mutant p53. Journal of Pathology 2017;241:661-70.
  31. Murphy DG, Risbridger GP, Bristow RG, Sandhu S. The Evolving Narrative of DNA Repair Gene Defects: Distinguishing Indolent from Lethal Prostate Cancer. European Urology 2017;71:748-9.
  32. Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP, Trial I. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. New England Journal of Medicine 2017;376:1027-37.
  33. Pleyer L, Dohner H, Dombret H, Seymour JF, Schuh AC, Beach CL, Swern AS, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, Thaler J, Halter B, Machherndl Spandl S, Zebisch A, Pichler A, Pfeilstocker M, Autzinger EM, Lang A, Geissler K, Voskova D, Sperr WR, Hojas S, Rogulj IM, Andel J, Greil R. Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group. International journal of molecular sciences 2017;18.
  34. Ravi Kumar AS, Tam C, Hofman MS. FDG PET in follicular lymphoma: more than a staging test? Leukemia & Lymphoma 2017;58:1521-3.
  35. Ravindran K, Gaillard F, Lasocki A. Distant spread of a supratentorial glioblastoma to the spinal cord. Journal of Clinical Neuroscience 2017;38:56-7.
  36. Rebello RJ, Kusnadi E, Cameron DP, Pearson HB, Lesmana A, Devlin JR, Drygin D, Clark AK, Porter L, Pedersen J, Sandhu S, Risbridger GP, Pearson RB, Hannan RD, Furic L. The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer. Clinical Cancer Research 2016;22:5539-52.
  37. Ringash J, Fisher R, Peters L, Trotti A, O'Sullivan B, Corry J, Kenny L, Van Den Bogaert W, Wratten C, Rischin D. Effect of p16 Status on the Quality-of-Life Experience During Chemoradiation for Locally Advanced Oropharyngeal Cancer: A Substudy of Randomized Trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART). International Journal of Radiation Oncology Biology Physics 2017;97:678-86.
  38. Rungruang BJ, Miller A, Krivak TC, Horowitz NS, Rodriguez N, Hamilton CA, Backes FJ, Carson LF, Friedlander M, Mutch DG, Goodheart MJ, Tewari KS, Wenham RM, Bookman MA, Maxwell GL, Richard SD. What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. Cancer 2017;123:985-93.
  39. Schroder J, Corbin V, Papenfuss AT. HYSYS: have you swapped your samples? Bioinformatics 2017;33:596-8.
  40. Seymour JF, Dohner H, Minden MD, Stone R, Gambini D, Dougherty D, Beach CL, Weaver J, Dombret H. Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia. Leukemia & Lymphoma 2017;58:1412-23.
  41. Sharp JA, Brennan AJ, Polekhina G, Ascher DB, Lefevre C, Nicholas KR. Dimeric but not monomeric alpha-lactalbumin potentiates apoptosis by up regulation of ATF3 and reduction of histone deacetylase activity in primary and immortalised cells. Cellular Signalling 2017;33:86-97.
  42. Shawky MS, Martin H, Hugo HJ, Lloyd T, Britt KL, Redfern A, Thompson EW. Mammographic density: a potential monitoring biomarker for adjuvant and preventative breast cancer endocrine therapies. Oncotarget 2017;8:5578-91.
  43. Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Pena L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L. Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. Annals of Oncology 2017;28:128-35.
  44. Skandarajah AR, Thomas S, Shackleton K, Chin-Lenn L, Lindeman GJ, Mann GB. Patient and medical barriers preclude uptake of tamoxifen preventative therapy in women with a strong family history. Breast 2017;32:93-7.
  45. Solomon B. First-line treatment options for ALK-rearranged lung cancer. Lancet 2017;389:884-6.
  46. Sucheston-Campbell LE, Cannioto R, Clay AI, Etter JL, Eng KH, Liu S, Battaglia S, Hu Q, Szender JB, Minlikeeva A, Joseph JM, Mayor P, Abrams SI, Segal BH, Wallace PK, Soh KT, Zsiros E, Anton-Culver H, Bandera EV, Beckmann MW, Berchuck A, Bjorge L, Bruegl A, Campbell IG, Campbell SP, Chenevix-Trench G, Cramer DW, Dansonka-Mieszkowska A, Dao F, Diergaarde B, Doerk T, Doherty JA, du Bois A, Eccles D, Engelholm SA, Fasching PA, Gayther SA, Gentry-Maharaj A, Glasspool RM, Goodman MT, Gronwald J, Harter P, Hein A, Heitz F, Hillemmanns P, Hogdall C, Hogdall EV, Huzarski T, Jensen A, Johnatty SE, Jung A, Karlan BY, Klapdor R, Kluz T, Konopka B, Kjaer SK, Kupryjanczyk J, Lambrechts D, Lester J, Lubinski J, Levine DA, Lundvall L, McGuire V, McNeish IA, Menon U, Modugno F, Ness RB, Orsulic S, Paul J, Pearce CL, Pejovic T, Pharoah P, Ramus SJ, Rothstein J, Rossing MA, Rubner M, Schildkraut JM, Schmalfeldt B, Schwaab I, Siddiqui N, Sieh W, Sobiczewski P, Song H, Terry KL, Van Nieuwenhuysen E, Vanderstichele A, Vergote I, Walsh CS, Webb PM, Wentzensen N, Whittemore AS, Wu AH, Ziogas A, Odunsi K, Chang-Claude J, Goode EL, Moysich KB, Australian Ovarian Cancer S. No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. Cancer Epidemiology Biomarkers & Prevention 2017;26:420-4.
  47. Sun Y, Reynolds H, Wraith D, Williams S, Finnegan ME, Mitchell C, Murphy D, Ebert MA, Haworth A. Predicting prostate tumour location from multiparametric MRI using Gaussian kernel support vector machines: a preliminary study. Australasian Physical & Engineering Sciences in Medicine 2017;40:39-49.
  48. Wang LL, Wallis CJ, Sathianathen N, Lawrentschuk N, Murphy DG, Nam R, Moon D. 'ProtecTion' from overtreatment: does a randomized trial finally answer the key question in localized prostate cancer? BJU International 2017;119:513-4.
  49. White V, Daly C, Anazodo A, Bibby H, Orme LM, Pinkerton R, Pole JD, Thompson K, Nathan PC, Baxter NN, Gupta S. The Australian-Canadian Adolescent and Young Adult Collaborative Cohort Initiative: Initial Meeting Report. Journal of Adolescent and Young Adult Oncology 2017;6:1-5.
  50. Yeh P, Dickinson M, Ftouni S, Hunter T, Sinha D, Wong SQ, Agarwal R, Vedururu R, Doig K, Fong CY, Blombery P, Westerman D, Dawson MA, Dawson SJ. Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes. Blood 2017;129:1685-90.
  51. Yeh P, Hunter T, Sinha D, Ftouni S, Wallach E, Jiang D, Chan YC, Wong SQ, Silva MJ, Vedururu R, Doig K, Lam E, Arnau GM, Semple T, Wall M, Zivanovic A, Agarwal R, Petrone P, Jones K, Westerman D, Blombery P, Seymour JF, Papenfuss AT, Dawson MA, Tam CS, Dawson SJ. Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia. Nature Communications 2017;8:14756.

Health Sciences Library [MAP]

PO Royal Melbourne Hospital

PARKVILLE, VIC 3050, AUSTRALIA

Phone: (03) 9342 8617; Fax: (03) 9342 8615

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Learning Resource Centre [MAP]

Level 7A, Peter MacCallum Cancer Centre

305 Grattan Street

MELBOURNE, VIC 3000, AUSTRALIA

Phone: (03) 8559 7194

 

Library Manager

Susan Monaghan;

Phone: (03) 9342 7346

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Health Sciences Library (RMH Building)

Hours (February - November):

Monday - Thursday: 8.30am - 6pm

Friday: 8.30am - 5pm

Summer Hours (December - January):

Monday - Friday: 8:30am - 5pm 


Learning Resource Centre (Peter MacCallum Building)

Staffed Hours (January - December):

Monday - Thursday: 10am - 2pm